<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Shares of Novavax Inc. NVAX, -6.03% gained 0.9% in premarket trading on Thursday after the company said its COVID-19 vaccine received conditional authorization in the U.K. The protein-based vaccine, which is called Nuvaxovid, requires two shots spaced 21 days apart and can be used in adults. The U.K. has already ordered up to 60 million doses of Novavax’s vaccine.
...read full article on Market Watch
